Risk management has become a top-of-mind issue for C-suites and boards around the world—nowhere more than in pharmaceutical companies. In a politically and economically turbulent environment, the risks pharma companies face, especially in clinical-trial design and execution, drug approval, product quality, and global commercial practices, are increasing in both frequency and magnitude.
{iframe}https://www.mckinsey.com/business-functions/risk/our-insights/expanding-horizons-for-risk-management-in-pharma?cid=other-eml-alt-mip-mck-oth-1806&hlkid=0a902f505d50450f9c91d9f83deb6bd6&hctky=3027237&hdpid=1588a3b2-0265-485b-a051-d38e1f1c489c{/iframe}